Current Clinical Applications of In Vivo Gene Therapy with AAVs
Jerry R. Mendell,Samiah A. Al-Zaidy,Louise R. Rodino-Klapac,Kimberly Goodspeed,Steven J. Gray,Christine N. Kay,Sanford L. Boye,Shannon E. Boye,Lindsey A. George,Stephanie Salabarria,Manuela Corti,Barry J. Byrne,Jacques P. Tremblay
DOI: https://doi.org/10.1016/j.ymthe.2020.12.007
IF: 12.91
2021-02-01
Molecular Therapy
Abstract:Hereditary diseases are caused by mutations in genes, and more than 7,000 rare diseases affect over 30 million Americans. Since more than 30 years, hundreds of researchers have sustained that genetic modifications would provide effective treatments for many inherited human diseases, offering durable and possibly curative clinical benefit with a single treatment.This review is limited to gene therapy using Adeno associated Virus (AAV) because the gene delivered by this vector do not integrate into the patient genome and has a low immunogenicity.There are now five treatments approved for commercialization and currently available, i.e., Luxtura, Zolgensma, the two CAR-T therapies (Yescarta and Kymriah) and Strimvelis (the gammaretrovirus approved for ADA-SCID in Europe). Dozens of other treatments are under clinical trials. The review article presents a broad overview of the field of therapy by in vivo gene transfer. We review gene therapy for neuromuscular disorders (spinal muscular atrophy (SMA), Duchenne muscular dystrophy (DMD), X-linked myotubular myopathy (XMTM), diseases of the central nervous system (including Alzheimer's Disease, Parkinson's Disease, Canavan Disease, Aromatic Amino Acid Decarboxylase Deficiency, Giant Axonal Neuropathy) and ocular disorders (Leber congenital amaurosis, age related macular degeneration (AMD), Choroideremia, Achromatopsia, Retinitis Pigmentosa and X-linked retinoschisis), the bleeding disorder hemophilia, and lysosomal storage disorders.
genetics & heredity,medicine, research & experimental,biotechnology & applied microbiology